Skip to main content
. 2013 Feb 5;8(2):e55732. doi: 10.1371/journal.pone.0055732

Figure 5. The responses to cucurbitacin B treatment in endogenously expressed wt-BRCA1 breast cancer cells (MCF-7 and MDA-MB-231) and in the two different mutant BRCA1 breast cancer cells (MDA-MB-436 and HCC1937).

Figure 5

(A), Western blot analysis for BRCA1 of wild type BRCA1 cells and cells harboring mutant BRCA1. From left to right, MCF-7, MDA-MB-231, HCC1937 and MDA-MB-436, respectively. (B), The cytotoxic effect of cucurbitacin B on endogenously expressed wt-BRCA1 and mutant BRCA1 cells. Each cells were treated with 1, 10, 20, 40, 60, 80 and 100 µg/ml cucurbitacin B for 48 h. (C) and (D), Proliferative rate of the mutant BRCA1 cells after treated with 15 µg/ml cucurbitacin B showed significantly decreased compared with untreated cells, (* p<0.01).